MX2020002004A - Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. - Google Patents

Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.

Info

Publication number
MX2020002004A
MX2020002004A MX2020002004A MX2020002004A MX2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A MX 2020002004 A MX2020002004 A MX 2020002004A
Authority
MX
Mexico
Prior art keywords
alcoholic
invasive diagnostic
fatty liver
liver fibrosis
alcoholic fatty
Prior art date
Application number
MX2020002004A
Other languages
English (en)
Inventor
Rémy Hanf
John Brozek
Geneviève Cordonnier
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2020002004A publication Critical patent/MX2020002004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un nuevo método no invasivo para el diagnóstico de una esteatosis hepática no alcohólica, en particular, esteatohepatitis no alcohólica y/o fibrosis hepática.
MX2020002004A 2017-08-25 2018-08-27 Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica. MX2020002004A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306098 2017-08-25
EP17200028 2017-11-03
PCT/EP2018/073050 WO2019038456A1 (en) 2017-08-25 2018-08-27 NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS

Publications (1)

Publication Number Publication Date
MX2020002004A true MX2020002004A (es) 2020-10-05

Family

ID=63254739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002004A MX2020002004A (es) 2017-08-25 2018-08-27 Diagnostico no invasivo de esteatosis hepatica no alcoholica, esteatohepatitis no alcoholica y/o fibrosis hepatica.

Country Status (13)

Country Link
US (1) US20200248261A1 (es)
EP (1) EP3673078A1 (es)
JP (2) JP2020531023A (es)
KR (1) KR20200040848A (es)
CN (1) CN111032884A (es)
AU (1) AU2018320715A1 (es)
BR (1) BR112020003573A2 (es)
CA (1) CA3070038A1 (es)
IL (1) IL272869A (es)
MX (1) MX2020002004A (es)
PH (1) PH12020500164A1 (es)
SG (1) SG11202000748TA (es)
WO (1) WO2019038456A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3129339A1 (en) * 2019-03-13 2020-09-17 Genfit Diagnosis of non-alcoholic steatohepatitis
CN110346555B (zh) * 2019-06-04 2022-11-08 西安医学院 一种肝脏脂质代谢调控fxr蛋白硫氢化修饰的检测方法及应用
US20220241232A1 (en) * 2019-06-07 2022-08-04 Genfit Method for treatment of at risk patients
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2022029066A1 (en) * 2020-08-03 2022-02-10 Genfit Method for nash risk assessment
WO2022046779A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR102679687B1 (ko) 2021-04-06 2024-06-28 곽민진 비-알코올성 지방간염 비-인간 동물모델의 제조를 위한 조성물 및 이의 용도
US20250182890A1 (en) * 2022-02-10 2025-06-05 The Chinese University Of Hong Kong Shenzhen Research Institute Metabolic dysfunction-associated steatohepatitis biomarker compositions and applications thereof
EP4349918A1 (en) * 2022-10-06 2024-04-10 Sika Technology AG Method for producing batch material comprising renewable raw materials and bitumen for acoustic damping compositions
US20250017938A1 (en) * 2023-06-20 2025-01-16 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
CN118813778B (zh) * 2024-07-01 2025-10-21 北京泛生子基因科技有限公司 一种试剂盒、使用方法及存储介质
CN120108563B (zh) * 2025-01-24 2026-01-13 昆明理工大学 基于机器学习筛选抗hbv活性的fxr调节剂的方法
CN120236743B (zh) * 2025-05-29 2025-08-15 南昌大学 一种便携式智能非酒精脂肪肝检测方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012105826A1 (en) * 2011-02-01 2012-08-09 Erasmus University Medical Center Rotterdam Use of micrornas in diagnosis and therapy of aging
WO2013071502A1 (en) * 2011-11-17 2013-05-23 Genedia Biotech Co Ltd Mir-193a-3p and associated genes predict tumorigenesis and chemotherapy outcomes
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
WO2017046181A1 (en) 2015-09-14 2017-03-23 Genfit Methods for diagnosing and evaluating non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
WO2019038456A1 (en) 2019-02-28
US20200248261A1 (en) 2020-08-06
PH12020500164A1 (en) 2020-09-14
AU2018320715A1 (en) 2020-02-13
KR20200040848A (ko) 2020-04-20
CN111032884A (zh) 2020-04-17
CA3070038A1 (en) 2019-02-28
EP3673078A1 (en) 2020-07-01
IL272869A (en) 2020-04-30
BR112020003573A2 (pt) 2020-09-01
JP2023118802A (ja) 2023-08-25
SG11202000748TA (en) 2020-03-30
JP2020531023A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
ZA202001528B (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
PH12018502057A1 (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3454745A4 (en) DIAGNOSTIC ADJUSTMENT FOR HEALTH AND DISEASE
MA51454A (fr) Micro-organisme de production d'oligosaccharide de lait humain
HK1243322A1 (zh) 脂肪酸半胱胺缀合物和它们作为自噬的活化剂的用途
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3710831A4 (en) MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS OF THE HEPATER
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
PH12018500578A1 (en) Methods of treating inflammatory diseases
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2017066712A3 (en) Modulators of telomere disease
EP3088898A4 (en) Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents
WO2016183223A3 (en) Targeted protein contrast agents, methods of making, and uses thereof
EP3846843A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASES
MX2019000677A (es) Células miméticas de células b.
WO2017066796A3 (en) Modulators of telomere disease
EP4234536A3 (en) Amino-aryl-benzamide compounds and methods of use thereof
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
WO2016014992A3 (en) Compositions for treatment, diagnosis and prognosis of diseases
EP3586141B8 (en) Non-invasive diagnosis of fibrotic non-alcoholic steatohepatitis
EA202090569A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени